These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 33945366)

  • 1. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
    Hasanov E; Jonasch E
    Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
    Curry L; Soleimani M
    Future Oncol; 2024; 20(18):1251-1266. PubMed ID: 38639572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
    Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
    N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
    Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
    Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
    Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
    Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
    Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belzutifan: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1921-1927. PubMed ID: 34613603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?
    Shepherd STC; Drake WM; Turajlic S
    Eur J Cancer; 2023 Mar; 182():15-22. PubMed ID: 36708612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
    Suárez C; Vieito M; Valdivia A; González M; Carles J
    Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belzutifan: A Narrative Drug Review.
    Visweswaran V; Pavithran K
    Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
    Tsimafeyeu I
    J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
    Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
    Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
    Pelle E; Al-Toubah T; Morse B; Strosberg J
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
    Fallah J; Brave MH; Weinstock C; Mehta GU; Bradford D; Gittleman H; Bloomquist EW; Charlab R; Hamed SS; Miller CP; Dorff SE; Chambers WA; Mixter BD; Dinin J; Pierce WF; Ricks TK; Tang S; Donoghue M; Pazdur R; Amiri-Kordestani L; Ibrahim A; Beaver JA
    Clin Cancer Res; 2022 Nov; 28(22):4843-4848. PubMed ID: 35727604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
    Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
    J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma.
    Rioja P; Rey-Cardenas M; De Velasco G
    Cancer Treat Rev; 2024 Sep; 129():102801. PubMed ID: 39032449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations.
    Tekin B; Erickson LA; Gupta S
    Semin Diagn Pathol; 2024 Jan; 41(1):20-27. PubMed ID: 37980175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.